372 related articles for article (PubMed ID: 31683978)
1. Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.
Palumbo GA; Parrinello NL; Giallongo C; D'Amico E; Zanghì A; Puglisi F; Conticello C; Chiarenza A; Tibullo D; Raimondo FD; Romano A
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683978
[TBL] [Abstract][Full Text] [Related]
2. The role of myeloid-derived suppressor cells in hematologic malignancies.
Gunes EG; Rosen ST; Querfeld C
Curr Opin Oncol; 2020 Sep; 32(5):518-526. PubMed ID: 32675593
[TBL] [Abstract][Full Text] [Related]
3. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment.
Zhou J; Shen Q; Lin H; Hu L; Li G; Zhang X
J Cancer Res Clin Oncol; 2019 Feb; 145(2):329-336. PubMed ID: 30426212
[TBL] [Abstract][Full Text] [Related]
4. Alteration of functionality and differentiation directed by changing gene expression patterns in myeloid-derived suppressor cells (MDSCs) in tumor microenvironment and bone marrow through early to terminal phase of tumor progression.
Mahanti K; Saha J; Sarkar D; Pramanik A; Roy Chattopadhyay N; Bhattacharyya S
J Leukoc Biol; 2024 Apr; 115(5):958-984. PubMed ID: 38236200
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers.
Fan R; De Beule N; Maes A; De Bruyne E; Menu E; Vanderkerken K; Maes K; Breckpot K; De Veirman K
Front Immunol; 2022; 13():1016059. PubMed ID: 36304465
[TBL] [Abstract][Full Text] [Related]
6. Plasticity of myeloid-derived suppressor cells in cancer.
Tcyganov E; Mastio J; Chen E; Gabrilovich DI
Curr Opin Immunol; 2018 Apr; 51():76-82. PubMed ID: 29547768
[TBL] [Abstract][Full Text] [Related]
7. Tumour-activated liver stromal cells regulate myeloid-derived suppressor cells accumulation in the liver.
Zhang H; He G; Kong Y; Chen Y; Wang B; Sun X; Jia B; Xie X; Wang X; Chen D; Wei L; Zhang M; Zeng H; Chen H
Clin Exp Immunol; 2017 Apr; 188(1):96-108. PubMed ID: 28019655
[TBL] [Abstract][Full Text] [Related]
8. Immunological dysregulation in multiple myeloma microenvironment.
Romano A; Conticello C; Cavalli M; Vetro C; La Fauci A; Parrinello NL; Di Raimondo F
Biomed Res Int; 2014; 2014():198539. PubMed ID: 25013764
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-derived suppressor cells in hematological malignancies: friends or foes.
Lv M; Wang K; Huang XJ
J Hematol Oncol; 2019 Oct; 12(1):105. PubMed ID: 31640764
[TBL] [Abstract][Full Text] [Related]
10. Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice.
Bian Z; Shi L; Venkataramani M; Abdelaal AM; Culpepper C; Kidder K; Liang H; Zen K; Liu Y
Eur J Immunol; 2018 Mar; 48(3):532-542. PubMed ID: 29120053
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.
Ostrand-Rosenberg S; Fenselau C
J Immunol; 2018 Jan; 200(2):422-431. PubMed ID: 29311384
[TBL] [Abstract][Full Text] [Related]
12. Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles.
Arkhypov I; Lasser S; Petrova V; Weber R; Groth C; Utikal J; Altevogt P; Umansky V
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878277
[TBL] [Abstract][Full Text] [Related]
13. The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment.
Mi Y; Guo N; Luan J; Cheng J; Hu Z; Jiang P; Jin W; Gao X
Front Immunol; 2020; 11():737. PubMed ID: 32391020
[TBL] [Abstract][Full Text] [Related]
14. Conditioned media from the renal cell carcinoma cell line 786.O drives human blood monocytes to a monocytic myeloid-derived suppressor cell phenotype.
Okada SL; Simmons RM; Franke-Welch S; Nguyen TH; Korman AJ; Dillon SR; Gilbertson DG
Cell Immunol; 2018 Jan; 323():49-58. PubMed ID: 29103587
[TBL] [Abstract][Full Text] [Related]
15. Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets.
Szebeni GJ; Vizler C; Nagy LI; Kitajka K; Puskas LG
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27886105
[TBL] [Abstract][Full Text] [Related]
16. TIME Is a Great Healer-Targeting Myeloid Cells in the Tumor Immune Microenvironment to Improve Triple-Negative Breast Cancer Outcomes.
Singh S; Zhang XHF; Rosen JM
Cells; 2020 Dec; 10(1):. PubMed ID: 33374595
[TBL] [Abstract][Full Text] [Related]
17. Mutualistic Effects of the Myeloid-Derived Suppressor Cells and Cancer Stem Cells in the Tumor Microenvironment.
Tanriover G; Aytac G
Crit Rev Oncog; 2019; 24(1):61-67. PubMed ID: 31679221
[TBL] [Abstract][Full Text] [Related]
18. The Development and Homing of Myeloid-Derived Suppressor Cells: From a Two-Stage Model to a Multistep Narrative.
Karin N
Front Immunol; 2020; 11():557586. PubMed ID: 33193327
[TBL] [Abstract][Full Text] [Related]
19. Bio-HMGB1 from breast cancer contributes to M-MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC-like cells.
Su Z; Ni P; She P; Liu Y; Richard SA; Xu W; Zhu H; Wang J
Cancer Immunol Immunother; 2017 Mar; 66(3):391-401. PubMed ID: 27987020
[TBL] [Abstract][Full Text] [Related]
20. The CCAAT/Enhancer-Binding Protein Family: Its Roles in MDSC Expansion and Function.
Wang W; Xia X; Mao L; Wang S
Front Immunol; 2019; 10():1804. PubMed ID: 31417568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
